- Credit Amounts:
- CME: 1.00
- CPE: 1.00
- ASWB ACE: 1.00
- CNE: 1.00
- Cost: Free
- Release: Feb 16, 2024
- Expires: Feb 15, 2026
- Estimated Time to Complete:
1 Hour(s) -
Average User Rating:
(4 Ratings)
Q&A The ADA and Its Implications for Patients with OUD: A Workshop enduring module is a recording from the live Regularly Scheduled Series dated July 20, 2023. If you claimed credit for this session at the live meeting, you should not claim credit for this module.
Faculty
Assistant Professor
College of Medicine
Division of Hospital Medicine
Attending Physician
Addiction Consult and Education Services
University of Kentucky
Lexington, Kentucky
Needs Statement
Patients with opioid use disorder have a disability that is protected by the Americans with Disabilities Act (ADA), yet few patient care providers or patients are aware of what the protections are or how to file a case for an ADA violation. This talk will serve as a primer to explain how to advocate for increased access to medications for opioid use disorder and decrease in health inequities using the ADA.Target Audience
Peer Support Specialists, Care Navigators,Physicians, Nurses, Nurse Practitioners, Physician Assistants, Pharmacists, Social WorkersObjectives
Upon completion of this activity, participants will be able to:- Describe the Americans with Disabilities Act (ADA)
- Review evidence-based treatment of opioid use disorder (OUD) with medications for opioid use disorder (MOUD)
- Apply the ADA to patients with OUD
- Discuss landmark settlements with public entities to ensure ADA compliance for patients with OUD
Accreditation
In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CMEThis enduring material is designated for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
This training has been approved by the KBML as meeting the statutory requirements of HB1. 0723-H1.5-UKHC/Jul23
IPE Competencies
- Values/Ethics for Interprofessional Practice
- Roles/ Responsibilities
- Interprofessional Communication
- Teams and Teamwork
This knowledge-based activity will award 1.00 contact hour (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers. ASWB ACE
As a Jointly Accredited Organization, UK HealthCare CECentral is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. UK HealthCare CECentral maintains responsibility for this course. Social workers completing this course receive 1.00 clinical continuing education credit.CNE
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 nursing contact hour.
Faculty Disclosure
All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.None of the planners, faculty, and others in control of educational content for this educational activity have a relevant financial relationship(s) to disclose with ineligible companies.
The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include a discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.
Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation